Business Context and Reporting Period
This Form 6-K filing by Immatics N.V. is dated September 16, 2024. The report details proof-of-concept clinical data from the ongoing Phase 1 trial of TCER® IMA401, a bispecific T cell engager targeting MAGEA4 and MAGEA8 in solid tumors. The data cutoff for the clinical results is July 23, 2024.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the reporting period. However, it discloses a significant financial event regarding a prior collaboration: Immatics is not obligated to refund the $150 million upfront payment received from Bristol Myers Squibb (BMS) under a terminated agreement, nor is it required to pay future milestone payments to BMS.
Material Changes and Clinical Data
Clinical Trial Results (IMA401):
- Patient Population: 35 heavily pretreated patients treated across nine dose levels; 29 were evaluable for efficacy, with 17 receiving relevant doses and showing high target expression.
- Efficacy: In the 17 patients with relevant doses and high target levels, the objective response rate (ORR) was 29% (5/17) and the confirmed ORR was 25% (4/16). Disease control rate was 53%.
- Durability: Three of four confirmed responses were ongoing at 13+, 8+, and 3+ months.
- Safety: Treatment-related adverse events (TRAEs) occurred in 80% of patients. Grade ≥3 TRAEs were observed in 54% of patients. Common events included transient lymphopenia and cytokine release syndrome (CRS). Neutropenia was observed at high dose levels.
- Pharmacokinetics: Demonstrated a median half-life of 16.9 days, supporting a switch to every-two-weeks (q2w) dosing and potential for every-four-weeks (q4w) dosing.
Collaboration Termination:
Bristol Myers Squibb (BMS) notified Immatics on September 13, 2024, that it is terminating the collaboration agreement for IMA401, effective December 12, 2024. All development and commercialization rights will return to Immatics.
Guidance, Outlook, and Risks
Outlook: Immatics will retain full rights to IMA401 and intends to continue development. The pharmacokinetic data supports exploring longer dosing intervals, which may facilitate combination therapies with checkpoint inhibitors.
Risks and Contingencies:
- Clinical Risks: The data presented is preliminary and subject to further quality checks. The maximum tolerated dose has not yet been determined.
- Forward-Looking Statements: The filing contains forward-looking statements regarding trial timing, outcomes, and market opportunities, which are subject to uncertainties and risks detailed in the Company's Form 20-F.
- Operational Transition: A wind-down period with BMS is stipulated under the collaboration agreement.
Investor Verification Checklist
- Verify the financial impact of the BMS collaboration termination on future cash flow and milestone obligations.
- Confirm the timeline for the wind-down period with BMS and the transition of IMA401 rights.
- Monitor the determination of the maximum tolerated dose (MTD) in the ongoing Phase 1 trial.
- Review the durability of the 13+ month response in the context of the broader patient population.
- Assess the feasibility of the proposed q4w dosing schedule in future clinical designs.